Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia
3/5/2013 10:27:53 AM
More...
|
Unigene Laboratories, Inc. (UGNE) and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
11/27/2012 8:59:03 AM
More...
|
Unigene Laboratories, Inc. (UGNE) and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-Engineered" TXA127
9/19/2012 10:25:46 AM
More...
|
Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension
9/27/2011 10:17:43 AM
More...
|
Tarix Pharmaceuticals Enrolls First Patient in Phase 1 Clinical Study of TXA127 in Adult Patients Following Double Cord Blood Stem Cell Transplant
4/26/2011 6:52:17 AM
More...
|
Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
2/24/2011 7:36:54 AM
More...
|